
    
      This clinical investigation is intended to demonstrate the safety and effectiveness of the
      TactiFlexTM Ablation Catheter, Sensor EnabledTM (TactiFlex SE) for treating symptomatic
      drug-refractory paroxysmal atrial fibrillation. This clinical investigation will be conducted
      under an investigational device exemption (IDE) and is intended to support market approval of
      the TactiFlex SE catheter worldwide. Three hundred fifty-five (355) subjects will be enrolled
      at up to 50 investigational sites worldwide. This clinical investigation is sponsored by
      Abbott.

      The TactiFlex IDE Clinical Study will enroll a total of 355 subjects.
    
  